

Awny Farajallah, MD, FACP
Vice President, Head US Medical Oncology
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrence Township, NJ 08648
September 21, 2017
awny.farajallah@bms.com

NCCN Guidelines® Panel: Esophageal and Esophagogastric Junction Cancer Panel

Dear Panel Members:

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed OPDIVO® (nivolumab) clinical data that was presented at recent medical congresses, as outlined below, for the panel's consideration. Please find the following data enclosed:

- Updated results from ATTRACTION-01 (ONO-4538-07), a phase 2 study evaluating nivolumab monotherapy in patients with previously treated metastatic esophageal cancer, presented at the European Society for Medical Oncology (ESMO) 2017 Annual Meeting.¹
- Interim results from ATTRACTION-02 (ONO-4538-12), a phase 3 study of nivolumab monotherapy in previously treated advanced gastric or gastroesophageal junction cancer, presented at the American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI) 2017 Annual Meeting.²
- Updated results from ATTRACTION-02 (ONO-4538-12), a phase 3 study of nivolumab monotherapy in previously treated advanced gastric or gastroesophageal junction cancer, presented at ESMO 2017 Annual Meeting.³

Additionally, I am submitting the enclosed OPDIVO® clinical data that was published in The Lancet Oncology. Please find the following publications enclosed:

- Primary manuscript from ATTRACTION-01 (ONO-4538-07) was published on March 15, 2017. This phase 2 study evaluated nivolumab monotherapy in patients with previously treated esophageal cancer.⁴

The use of nivolumab for the treatment of esophageal cancer is considered investigational.⁵

Rationale: These data are submitted in response to a standing request from NCCN for new clinical data. The ATTRACTION-02 (ONO-4538-12) study evaluated the safety and efficacy of nivolumab compared to placebo as a treatment option in third or later line setting for advanced gastric or gastroesophageal cancer that was histologically confirmed as adenocarcinoma in all patients.

The following resources are included for your review:

1. Kitagawa Y, Doki Y, Kato K et al. Two Year Survival and Safety Update for Esophageal Squamous Cell Carcinoma Treated With Nivolumab (ATTRACTION-01/ONO-4538-07). Poster presented at: European Society for Medical Oncology (ESMO) Congress; September 8-12, 2017; Madrid, Spain.
2. Kang YK, Satoh T, Ryu MH, et al. Nivolumab (ONO-4538-12/BMS-936558) as salvage treatment after second- or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): a double-blinded, randomized, phase 3 trial. Oral presentation at: the 2017 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI); January 19-21, 2017; San Francisco, CA.
3. Boku N, Kang YK, Satoh T et al. A Phase III Study of Nivolumab in Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Updated Results and Subset Analysis by PD-L1 Expression (ATTRACTION-02). Oral Presentation at: European Society for Medical Oncology (ESMO) Congress; September 8-12, 2017; Madrid, Spain
4. Kudo T, Hamamoto Y, Kato K et al. Nivolumab Treatment for Oesophageal Squamous-Cell Carcinoma: An Open-Label, Multicentre, Phase 2 Trial. *Lancet Oncol* 2017;18: 631–39.
[http://dx.doi.org/10.1016/S1470-2045\(17\)30181-X](http://dx.doi.org/10.1016/S1470-2045(17)30181-X)



Bristol-Myers Squibb

5. Product information, OPDIVO® (nivolumab) injection, for intravenous infusion. Bristol-Myers Squibb Company, Princeton, NJ. July 2017.

Thank you for your consideration of this request.

Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical Oncology
Bristol-Myers Squibb Company
609-302-3927; awny.farajallah@bms.com